The present status of exogenous surfactant for the newborn.
This year is the 20th anniversary of the first successful trial of exogenous surfactant for respiratory distress syndrome in the newborn and it is perhaps a good time to review recent advances in basic science and clinical practice as they relate to surfactant therapy.
Curley
A E
AE
Regional Neonatal Unit, Royal Maternity Hospital, Grosvenor Road, BT12 6BB, Northern Ireland, Belfast, UK.
Halliday
H L
HL
D000818:Animals; D006023:Glycoproteins / Q000172:deficiency / Q000502:physiology; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D008171:Lung Diseases / Q000188:drug therapy; D051379:Mice; D008822:Mice, Transgenic; D011510:Proteolipids / Q000502:physiology; D037663:Pulmonary Surfactant-Associated Protein D; D037661:Pulmonary Surfactant-Associated Proteins; D011663:Pulmonary Surfactants / Q000172:deficiency / Q000502:physiology / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy
D006023:Glycoproteins; D011510:Proteolipids; D037663:Pulmonary Surfactant-Associated Protein D; D037661:Pulmonary Surfactant-Associated Proteins; D011663:Pulmonary Surfactants; D011994:Recombinant Proteins